Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
About this item
Full title
Author / Creator
Publisher
Boston, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Adoptive immunotherapy involving bolus-dose recombinant interleukin-2 (rIL-2) has been reported to induce tumor regression in some patients with cancer, but has been associated with severe fluid retention and cardiopulmonary stress. In an effort to preserve the efficacy but reduce the toxicity of this treatment, we used escalating doses of rIL-2 as...
Alternative Titles
Full title
Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_14783102
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_14783102
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJM198704093161502
